Comparative analyses of mutation frequencies between primary versus metastatic pancreatic adenocarcinomas revealed that the molecular features were similar across common genomic alterations, such as KRAS, TP53, CDKN2A/B and SMAD4, which were to be expected based on previous data8 (Fig. 1a). This evidence concerns the gene KRAS and pancreatic adenocarcinoma.